Inhibrx Biosciences (INBX) Competitors $24.45 +0.83 (+3.51%) Closing price 04:00 PM EasternExtended Trading$24.45 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALTShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Harrow Phibro Animal Health AbCellera Biologics Cogent Biosciences Pharvaris Intellia Therapeutics CureVac Aurinia Pharmaceuticals WAVE Life Sciences Calliditas Therapeutics AB (publ) Inhibrx Biosciences (NASDAQ:INBX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Is INBX or HROW more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -85.12% -58.90% Harrow -10.19%-25.01%-4.27% Does the media refer more to INBX or HROW? In the previous week, Harrow had 17 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 19 mentions for Harrow and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.93 beat Harrow's score of 0.40 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer INBX or HROW? Harrow has a consensus price target of $63.83, suggesting a potential upside of 77.86%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, INBX or HROW? Inhibrx Biosciences has higher earnings, but lower revenue than Harrow. Harrow is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K1,770.18$1.69B$116.750.21Harrow$199.61M6.60-$17.48M-$0.56-64.09 Do insiders and institutionals hold more shares of INBX or HROW? 82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 15.2% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, INBX or HROW? Inhibrx Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. SummaryInhibrx Biosciences and Harrow tied by winning 8 of the 16 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$341.92M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio0.218.2821.0120.09Price / Sales1,770.18303.17433.8199.01Price / Cash0.2042.5936.1658.27Price / Book2.657.678.125.65Net Income$1.69B-$55.28M$3.25B$257.91M7 Day Performance12.31%2.50%0.97%2.09%1 Month Performance60.75%11.70%7.36%11.13%1 Year Performance88.37%4.89%31.31%18.40% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences2.8243 of 5 stars$24.45+3.5%N/A+69.8%$341.92M$200K0.21166News CoverageHigh Trading VolumeHROWHarrow2.3814 of 5 stars$35.62+2.0%$63.83+79.2%+43.7%$1.31B$199.61M-63.61180Trending NewsAnalyst RevisionPAHCPhibro Animal Health4.0498 of 5 stars$31.54+2.4%$24.40-22.6%+56.3%$1.28B$1.02B40.441,940News CoverageABCLAbCellera Biologics2.3189 of 5 stars$4.24+5.7%$8.75+106.4%+15.7%$1.27B$28.83M-7.57500High Trading VolumeCOGTCogent Biosciences3.5461 of 5 stars$11.09+1.0%$18.00+62.3%+35.9%$1.26BN/A-6.0380Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumePHVSPharvaris1.3966 of 5 stars$23.80-5.3%$36.20+52.1%+29.2%$1.24BN/A-7.9130High Trading VolumeNTLAIntellia Therapeutics4.4128 of 5 stars$11.95+3.6%$33.37+179.2%-56.8%$1.24B$57.88M-2.28600Gap UpCVACCureVac4.7525 of 5 stars$5.46flat$6.83+25.2%+47.9%$1.22B$579.18M5.93880Positive NewsAUPHAurinia Pharmaceuticals3.2887 of 5 stars$9.04+2.7%$11.50+27.2%+55.3%$1.22B$235.13M32.29300Positive NewsWVEWAVE Life Sciences4.5817 of 5 stars$7.84+1.8%$20.50+161.5%+35.5%$1.22B$108.30M-9.33240Analyst ForecastCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Harrow Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Cogent Biosciences Alternatives Pharvaris Alternatives Intellia Therapeutics Alternatives CureVac Alternatives Aurinia Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Calliditas Therapeutics AB (publ) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
